fda compounding semaglutide warning letters september 2025 Out of Shortage, Into Controversy: The Fight Over GLP-1 FDA Issues Warning Letters to

,

Workspace and Vial Preparation Before any vial is opened, the workspace should be clean and the equipment laid out within reach

Managing Common Gastrointestinal Side Effects Because GLP-1 agonists directly impact how quickly the stomach processes food, many patients experience gastrointestinal symptoms during the initial weeks of treatment

Retatrutide (LY3437943), developed by Eli Lilly, is an investigational once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

This review summarizes the discovery of GLP-1 and the development of GLP-1RAs, with a particular focus on their central mechanisms of action